CN100446791C - Chinese medicinal composition for treating hemorrhagic brain contusion and laceration - Google Patents
Chinese medicinal composition for treating hemorrhagic brain contusion and laceration Download PDFInfo
- Publication number
- CN100446791C CN100446791C CNB2004100408233A CN200410040823A CN100446791C CN 100446791 C CN100446791 C CN 100446791C CN B2004100408233 A CNB2004100408233 A CN B2004100408233A CN 200410040823 A CN200410040823 A CN 200410040823A CN 100446791 C CN100446791 C CN 100446791C
- Authority
- CN
- China
- Prior art keywords
- present
- radix
- blood
- laceration
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002008 hemorrhagic effect Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 208000029028 brain injury Diseases 0.000 title abstract description 4
- 206010052346 Brain contusion Diseases 0.000 title abstract 2
- 230000009516 brain contusion Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 45
- 210000004556 brain Anatomy 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 208000034656 Contusions Diseases 0.000 claims description 12
- 208000034693 Laceration Diseases 0.000 claims description 12
- 230000009519 contusion Effects 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 1
- 229940126680 traditional chinese medicines Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 238000002360 preparation method Methods 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 5
- 230000035619 diuresis Effects 0.000 abstract description 5
- 238000011443 conventional therapy Methods 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 2
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 2
- 244000248825 Peltandra virginica Species 0.000 abstract 2
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 239000012567 medical material Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010048962 Brain oedema Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000000680 avirulence Effects 0.000 description 4
- 208000006752 brain edema Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000008558 metabolic pathway by substance Effects 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241001566735 Archon Species 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010020067 Histaglobin Proteins 0.000 description 1
- 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine composition for treating hemorrhagic brain contusions and lacerations. The present invention is prepared from ten Chinese medicines, such as peach seed, safflower, chuanxiong, angelica, rehmannia root, tuckahoe, astragalus root, etc. The present invention has scientific and unique composition; medicines for stimulating blood circulation to remove blood stasis are used, and the rehmannia root and the angelica are used so as to remove the blood stasis but not to damage yin blood; the astragalus root can add the effect of removing the blood stasis and can cooperate mutually with the tuckahoe to strengthen the effect of nourishing qi to cause diuresis but not to damage vital qi. The present invention is the unique compound Chinese medicinal preparation for treating brain traumas at present and has stable ingredient properties; proved by pharmacodynamic toxicological tests of animals and clinical test research, the therapeutic effect of the Chinese medicine composition has obvious advantages over the therapeutic effect of conventional therapy, and the Chinese medicine composition has no toxic side effect. The present invention can be made into various acceptable oral taking preparations in pharmacy.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hemorrhagic contusion and laceration of brain, specifically be a kind of be the Chinese patent medicine of feedstock production with Chinese medicine.
Technical background
Hemorrhagic contusion and laceration of brain is modal one of type of hindering in the craniocerebral trauma, accounts for the 20%--40% of craniocerebral trauma.Its main pathological lesion is cerebral tissue fragmentation, necrosis, hemorrhage, edema and cerebral microvascular thromboembolism.These pathological lesions not only can directly cause delayed ischemic neurological deficits, secondary intracranial pressure rising threat to life, and be to cause brain injury kitchen range and surrounding tissue to carry out the major reason of ischemia, anoxia, acidosis and brain cell degeneration necrosis, influence traumatic condition and lapse to life quality with the wounded.Doctor trained in Western medicine mainly is to use medicines such as dehydration, hemostasis and hormones to treatment light, medium-sized hemorrhagic contusion and laceration of brain, though certain curative effect is arranged, but it is still not ideal enough, and more side effect is arranged, can cause Water-Electrolyte disorder and renal function injury as dehydrant mannitol, hormone can cause hyperglycemia, digestive tract hemorrhage, reduces Abwehrkraft des Koepers, increase wound infection, hemorrhage can cause wound hindbrain ischemic lesions.
The content of invention
Technical problem to be solved by this invention provides a kind of treatment by Chinese herbs oral formulations activating blood and removing stasis and QI invigorating eliminating dampness by diuresis effect, that hemorrhagic contusion and laceration of brain had obvious curative effects that has.
The technical solution used in the present invention is based on tcm theory.Theory of Chinese medical science is thought: " blood vessels are obstructed, and QI and blood is become silted up and hindered "." the capable then blood of gas is capable, gas end then blood ends "." blood circulating out of vessels is all the stasis of blood ".The brain inner blood smoulders or congestion stops up, and is all syndrome of blood stasis, and blood-vessel obstructive causes the stasis of QI and blood phlegm-damp and stops amassing, and influences spleen, lung, three organ function imbalances of kidney simultaneously, satisfies and gives birth to phlegm-damp, and the expectorant heresy is disturbed the heart and caused cerebral edema.Hemorrhagic contusion and laceration of brain, intracerebral hematoma and hypertensive cerebral hemorrhage etc. belong to this card, and method of treatment palpus activating blood and removing stasis and the same usefulness of QI invigorating eliminating dampness by diuresis have Semen Persicae, Flos Carthami and Rhizoma Chuanxiong etc. as the activating blood and removing stasis medicine, and the invigorating vital QI medicine has the Radix Astragali, Radix Glycyrrhizae etc., and damp-clearing drug has Poria etc.
According to above-mentioned theory, medicine of the present invention is made by the following components by weight parts proportioning:
Semen Persicae 4-10 Flos Carthami 3-10 Rhizoma Chuanxiong 3-10
Radix Paeoniae Rubra 6-12 Radix Angelicae Sinensis 4-10 Radix Rehmanniae 9-15
Poria 9-15 Radix Astragali 9-30 Radix Angelicae Dahuricae 3-10
Radix Glycyrrhizae 1-9
In aforementioned pharmaceutical compositions, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Paeoniae Rubra activating blood and removing stasis, wind-expelling pain-stopping are monarch drug; Radix Rehmanniae heat clearing and blood cooling is equipped with the Radix Angelicae Sinensis nourishing blood and promoting blood circulation and moisturizes, and makes blood stasis dispelling and non-impairment of YIN blood is ministerial drug; Radix Angelicae Dahuricae anti-inflammatory analgetic, priming is up, the Poria promoting diuresis to eliminate damp pathogen, and Radix Astragali QI invigorating diuretic is an adjuvant drug, Radix Astragali QI invigorating diuretic, the capable then blood of gas is capable, not only strengthens the effect of blood stasis dispelling, and uses the effect that can also strengthen the QI invigorating diuretic together with Poria, make diuretic and do not hinder healthy energy, help the absorption of cerebral edema, strengthen the brain cell hypoxia-bearing capability, alleviate the cerebral tissue secondary lesion; Radix Glycyrrhizae invigorating the spleen and replenishing QI, coordinating the actions of various ingredients in a prescription are messenger drug.The synergism of each component and produce activating blood and removing stasis, the effect of QI invigorating eliminating dampness by diuresis is the double medicine of controlling of blood stasis and edema.In addition, the medical material avirulence medical material of compatibility, incompatibilitys such as no eighteen incompatible medicaments, nineteen medicaments of mutual restraint.
The specific embodiment
1, the preferred weight portion ratio range of preparation medicine of the present invention is:
Semen Persicae 6-9 Flos Carthami 5-9 Rhizoma Chuanxiong 5-9
Radix Paeoniae Rubra 7-12 Radix Angelicae Sinensis 6-9 Radix Rehmanniae 11-15
Poria 10-14 Radix Astragali 12-25 Radix Angelicae Dahuricae 5-9
Radix Glycyrrhizae 5-7
2, optimum weight part proportioning of medicine of the present invention is:
Semen Persicae 10 Flos Carthamis 10 Rhizoma Chuanxiongs 10
Radix Paeoniae Rubra 12 Radix Angelicae Sinensis 10 Radix Rehmanniae 12
Poria 12 Radixs Astragali 12 Radixs Angelicae Dahuricae 10
Radix Glycyrrhizae 5
3, preparation technology and usage
(1), take by weighing medical material, put that water cleans twice in the bulk container, move in the multi-function extractor water and carry by proportion relation; 10 times of water gagings that add medical material weight for the 1st time decocted 1 hour, add 8 times of water gagings the 2nd, 3 time to decoct 40 minutes, and filter cleaner, merging filtrate is condensed into the clear paste (temperature is 70 ℃ in jar) of 1: 1 ratio with thin film concentrator; Clear paste is put and is left standstill cooling at least 16 hours in the container; Get supernatant and filter, remove precipitate, be condensed into the thick paste (interior temperature 60--70 ℃ of jar) of 1.38-1.40 proportion with the vacuum decompression concentrator with high speed centrifuge; Get 4 parts of thick pastes, 1 part of sucrose, 0.5 part in dextrin is granulated (temperature is 70 ℃ in jar) granulate with airpillow-dry granulator; Granule restrains (amounting to crude drug 24.6 grams) packing with automatic packaging machine by every bag 10 after the assay was approved.
Except above-mentioned preparation technology, can be prepared into the pharmaceutically various peroral dosage forms of acceptable.
(2), this preparation is brown granular, the sweet little hardship of distinguishing the flavor of.Be used for light, medium-sized hemorrhagic contusion and laceration of brain etc.Take after mixing it with hot water, adult every day 3 times, each 1 bag (10 gram), 7-10 day was 1 course of treatment.Be not taken by pregnant women.
4, composition qualitative identification
Use that specificity is strong, highly sensitive, the thin layer chromatography of favorable reproducibility is to carrying out qualitative identification according to main Chinese medicinal materials in three batches of drug particles of above-mentioned explained hereafter, and contrast with positive medical material and negative control (not containing this preparation that will differentiate medical material), obtain the identical table 1 that the results are shown in.
Three batches of this preparation compositions of table 1 qualitative identification
Annotate :+positive, this medical material is promptly arranged;-negative, promptly there is not this medical material.
The result shows that this preparation medicine material component is stable.
5, animal experiment study
(1), this preparation of maximum dosage-feeding experimental evidence theories of Chinese materia medica does not contain the toxicity medical material and clinical practice has no side effect, and judges that this preparation is difficult for measuring LD50, selects the maximum dosage-feeding test.64 of Kunming kind healthy mices (male and female each half) are divided into four groups at random: irritate 10%, 45% and 60% preparation aqueous solution 1ml of stomach 1 time, (dosage is the 5g/kg body weight to be respectively 25 times of groups, be equivalent to be grown up 25 times of 1 dosage are below analogized), 112.5 times of groups (22.5g/kg body weight) and 150 times of groups (30g/kg body weight); Matched group is irritated stomach 0.9% sodium chloride injection 1ml 1 time.Irritated stomach preceding 1 day and back 7 days title mice body weight, observe 7 days mices behind the filling stomach continuously and have or not toxic reaction and death toll.The results are shown in table 2
Body weight and the mortality rate of four groups of mices of table 2
Body weight is animal appetite, take food, digest and assimilate and the concentrated expression of substance metabolism, increases equally than average weight before the administration and matched group after all survival mice administrations, shows that this preparation has no adverse effects to these links of mice.No poisoning clinical manifestation, well-known, 0.9% sodium chloride injection avirulence, and drug toxicity usually be directly proportional to medicament, 112.5 and 150 times of groups do not have death as known from Table 2, and death appears in matched group and 25 times of groups on the contrary, and its reason may or be irritated stomach with individual body constitution difference and be caused damaging relevant.
The conclusion mice is to suitable 150 times of 1 dosage of adult of 1 maximum dosage-feeding of this preparation, and (the 30g/Kg body weight is amounted to crude drug 73.8g/Kg), no toxic reaction and death in 7 days illustrate this preparation avirulence, and is consistent with theories of Chinese materia medica and clinical practice result.
(2), the healthy Wistar rat of long term toxicity test is 97 (male 49, female 48) be divided into 4 groups at random, point of accumulation in the time of 3: irritate 10%, 20% and 40% each 2ml of preparation of stomach, every day 2 times, continuous 10 days, be respectively low dose group (L group), middle dosage group (M group) and high dose group (H group), matched group (C group) is only irritated stomach 0.9% sodium chloride injection 2ml, also be every day 2 times, continuous 10 days.Respectively organize rat blood routine and biochemical index with full-automatic medical check analysis instrument and the detection of former installed reagents, carry out general clinical observation, body weight and pathological examination simultaneously.Observe week aspire to irritating for the 1st time behind the stomach the 11st, 21 and 31 day.The result is as follows:
(the comparison of x ± S) of four groups of the 11st day blood routine hepatic and renal function indexs of table 3
Annotate: 3 administration groups of t check are compared the P value all greater than 0.05 with matched group.
(the comparison of x ± S) of four groups of the 21st day blood routine hepatic and renal function indexs of table 4
Annotate: all high C group of packed cell volume L, M group; H group is compared the low and Archon ratio height of leukocyte count with the C group, 3 administration groups of all the other indexs are compared the P value all greater than 0.05 with matched group
(the comparison of x ± S) of four groups of the 31st day blood routine hepatic and renal function indexs of table 5
Annotate: 3 administration group serum creatinines are starkly lower than matched group, and the L Histaglobin is higher than matched group, and 3 administration groups of all the other indexs are compared the P value all greater than 0.05 with matched group
(the comparison of x ± S) of point of accumulation body weight during four groups three in table 6
Annotate: organize weight increase than irritating stomach preceding the 31st day C, L, M after irritating stomach, all the other P values all greater than 0.05,3 administration group each the time point of accumulation when corresponding with matched group point of accumulation to compare the P value also all be greater than 0.05.
This test of clinical meaning of leading indicator is under diet situation the same terms, and body weight reflects the situation of rats eating, digestion, absorption and substance metabolism; Peripheral hemogram can also reflect the hemopoietic tissue function to a certain extent except reflecting situation own; The ability of total protein, albumin and globulin reflection protein metabolism and liver synthetic protein; Paddy third and glutamic oxaloacetic transaminase, GOT raise and reflect that hepatocyte, cardiac muscle and kidney are undermined; Total bilirubin raises, and the disintegrate of reflection red blood cell aging increases or biliary excretion is obstructed; Hematuria element, serum creatinine raise and reflect renal insufficiency; The dysfunction of blood sugar increasing reflection pancreatic secretion insulin.Be lower than the C group (but still at lower limits of normal) except that the 21st day H group of leukocyte count as can be known from table 3-6, this preparation has no adverse effects to exhausted most part index number, shows these histoorgan avirulences.
All activities in rats are normal, impassivity systemic symptom and sign, feed, fur, mucosa and defecate no abnormal.The difference not statistically significant of 3 administration group pathological changes and matched group.
This preparation of conclusion quite is grown up 12.2 times for the rat consumption per day, and continuous 10 days to non-toxic reactions such as the heart, liver and gall, pancreas, spleen, kidney, lung, hemopoietic tissue, nervous system and substance metabolismes.
6, pharmacodynamic experiment healthy rabbits 68 (body weight 2.5-3.0kg) is divided into two groups at random.The treatment group: preceding 1 week of causing injury is made stomach fistulation pipe art, copies Feeney freely falling body method to cause contusion and laceration of brain, hinders and injects this preparation 8ml/kg/ day through stomach fistulation pipe in back 6 hours, divides 3 times, and continuous 21 days, 1ml contained crude drug 0.4g; Matched group substitutes outside this preparation divided by the isometric(al) normal saline, and all the other conditions are identical with the treatment group.Long-pending with technical measurement brain injury stoves such as graphical analyses, observe pathological changes such as cerebrovascular and blood-brain barrier permeability.Mainly the results are shown in table 7
Table 7 liang group is hindered the comparison of back leading indicator
Annotate: +++expression severe or volume; ++ expression moderate or middle amount; + represent slight or a small amount of;-expression does not have.
As known from Table 7, all repair with prolonging observing time for two groups, but the treatment group is faster than matched group reparation, the 21st day result also is like this.Show that this preparation can promote the absorption of cerebral hemorrhage and edema, reduce microthrombusis in the blood vessel, improve brain microcirculation, reduce the permeability of blood brain barrier, strengthen phagocytic function, alleviate the neuron secondary lesion, make and hindered the kitchen range healing early 7 days.
7, clinical and experimental study
The acute brain wound wounded 94 examples of Glasgow coma scale (GCS) 6-15 branch (traumatic condition is by heavy extremely light) traumatic condition are divided into two groups by the admission number odevity.The Western medicine group: male's 29 examples, women's 17 examples, totally 46 examples, 36.0 ± 14.3 years old mean age, GCS 10.25 ± 2.68 minutes dewaters, doctor trained in Western medicine conventional therapy such as hemostasis and hormone.Chinese drug-treated group: male's 28 examples, women's 20 examples, totally 48 examples, 35.2 ± 14.9 years old mean age, GCS 10.23 ± 2.70 minutes, oral or this preparation of nasal feeding (1ml contains crude drug 0.4g), every day, 4ml/kg divided 3 administrations, and 7 was 1 course of treatment, treatment 1-3 course of treatment.Two groups are all used antibiotic prophylaxis to infect.Cranium brain CT examination is to measure the amount and the edema degree of cerebral hemorrhage; Measure hemorheology index, blood plasma superoxide dismutase activity and lipid peroxidation product content etc.; Hinder and followed up a case by regular visits in back 3 months, the evaluation of GCS final result adopts 5 point-scores to estimate rehabilitation situation.The results are shown in table 8-9.
Table 8 liang the 15th day test rating result's of group comparison
Annotate: * represents to compare P＜0.05 or P＜0.01 with the Western medicine group; The the 3rd, 7 day Chinese drug-treated group of ▲ expression is starkly lower than the Western medicine group.
The check result of table 9 liang group treatment back leading indicator
Annotate: the data of all indexs and Western medicine group compared P＜0.05 or P＜0.01 in * represented.
From table 8-9 as can be known, this preparation can promote the absorption of cephalophyma and cerebral edema, alleviates or eliminates clinical symptoms and sign, improves cure rate, and aspects such as reduction disability rate are better than the Western medicine group.This external hemorheology properties of improving is regulated aspects such as body fibrinolytic-coagulation function and lipoid peroxidization resistant and also obviously is better than the doctor trained in Western medicine conventional therapy.
The effect of this preparation for treating of conclusion acute brain traumatic patient is apparently higher than the doctor trained in Western medicine conventional therapy.
Claims (4)
1, a kind of Chinese medicine composition for the treatment of hemorrhagic contusion and laceration of brain is characterized in that the medicament of being made by following weight proportion by following traditional Chinese medicines:
Semen Persicae 4-10 Flos Carthami 3-10 Rhizoma Chuanxiong 3-10
Radix Paeoniae Rubra 6-12 Radix Angelicae Sinensis 4-10 Radix Rehmanniae 9-15
Poria 9-15 Radix Astragali 9-30 Radix Angelicae Dahuricae 3-10
Radix Glycyrrhizae 1-9.
2,, it is characterized in that the weight proportion of described each Chinese medicine is according to the Chinese medicine composition of the described treatment hemorrhagic contusion and laceration of brain of claim 1:
Semen Persicae 10 Flos Carthamis 10 Rhizoma Chuanxiongs 10
Radix Paeoniae Rubra 12 Radix Angelicae Sinensis 10 Radix Rehmanniae 12
Poria 12 Radixs Astragali 12 Radixs Angelicae Dahuricae 10
Radix Glycyrrhizae 5.
3, the Chinese medicine composition of treatment hemorrhagic contusion and laceration of brain according to claim 1 and 2 is characterized in that, its medicament is any peroral dosage form that can prepare on pharmaceutics.
4, the medicine of treatment hemorrhagic contusion and laceration of brain according to claim 3 is characterized in that, its dosage form comprises mixture, granule and oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100408233A CN100446791C (en) | 2004-10-09 | 2004-10-09 | Chinese medicinal composition for treating hemorrhagic brain contusion and laceration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100408233A CN100446791C (en) | 2004-10-09 | 2004-10-09 | Chinese medicinal composition for treating hemorrhagic brain contusion and laceration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634249A CN1634249A (en) | 2005-07-06 |
| CN100446791C true CN100446791C (en) | 2008-12-31 |
Family
ID=34845869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100408233A Expired - Fee Related CN100446791C (en) | 2004-10-09 | 2004-10-09 | Chinese medicinal composition for treating hemorrhagic brain contusion and laceration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100446791C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832871A (en) * | 2016-04-28 | 2016-08-10 | 刘瑞英 | Traditional Chinese medicine for treating cerebral contusion and laceration |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740195B (en) * | 2015-03-03 | 2018-01-30 | 马文金 | A kind of Chinese medicine hemostatic powder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125107A (en) * | 1994-12-22 | 1996-06-26 | 蒋争鸣 | Naoyujing medicine for curing traumatic intracranial hematoma |
-
2004
- 2004-10-09 CN CNB2004100408233A patent/CN100446791C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125107A (en) * | 1994-12-22 | 1996-06-26 | 蒋争鸣 | Naoyujing medicine for curing traumatic intracranial hematoma |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832871A (en) * | 2016-04-28 | 2016-08-10 | 刘瑞英 | Traditional Chinese medicine for treating cerebral contusion and laceration |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634249A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN101396466A (en) | Cold medicine tea composition as medicine and food, preparation method and use thereof | |
| CN102940779A (en) | Medicine composition for treating chronic ulcerative colitis and preparation process of medicine composition | |
| CN102626468B (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN111729055A (en) | Preparation method and application of traditional Chinese medicine composition for eliminating dampness and removing toxicity | |
| CN104435990A (en) | Traditional Chinese medicinal composition for promoting recovery of gastrointestinal function after abdominal operation and preparation method of traditional Chinese medicinal composition | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN105796926A (en) | Traditional Chinese medicine composition for treating alopecia and preparation method thereof | |
| CN1121867C (en) | Medicine for preventing and treating abortion | |
| CN100446791C (en) | Chinese medicinal composition for treating hemorrhagic brain contusion and laceration | |
| CN108498755A (en) | Treat the Chinese medicine composition and its preparation method and application of cardiovascular and cerebrovascular disease | |
| CN114869928A (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN1083269C (en) | Chinese herbal medicine for treating hysteromyoma and breast fibrosarcoma and its prepn. method | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN101439109A (en) | Chinese herbal medicinal composition for treating enterogastric disease and preparation method and use | |
| CN114767803B (en) | Dendrobium officinale traditional Chinese medicine composition for down-regulating kidney PDZK1 protein to prevent hyperuricemia, and preparation method and application thereof | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN114288346A (en) | Traditional Chinese medicine composition for treating recurrent abortion and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANXI JINHUA HUIXING PHARMACY CO., LTD. Effective date: 20141027 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Xianrong Inventor after: Hong Duolun Inventor after: Feng Hua Inventor after: Zhu Gang Inventor after: Gao Qian Inventor after: Yu Haiyong Inventor before: Wang Xianrong Inventor before: Hong Duolun Inventor before: Feng Hua Inventor before: Zhu Gang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG XIANRONG HONG DUOLUN FENG HUA ZHU GANG TO: WANG XIANRONG HONG DUOLUN FENG HUA ZHU GANG GAO QIAN YU HAIYONG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141027 Address after: 400038 Chongqing city gaotanyan Southwest Hospital Patentee after: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA Patentee after: SHANXI JINHUA HUIXING PHARMACY Co.,Ltd. Address before: 400038 Chongqing city gaotanyan Southwest Hospital Patentee before: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20210723 Address after: 400038 Chongqing Shapingba gaotanyan Southwest Hospital Patentee after: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA Address before: 400038 Chongqing city gaotanyan Southwest Hospital Patentee before: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA Patentee before: SHANXI JINHUA HUIXING PHARMACY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 Termination date: 20211009 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |